OncoMatch/Clinical Trials/NCT06810609
Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC
Is NCT06810609 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Immunotherapy for lung cancer non-small cell cancer (nsclc).
Treatment: Immunotherapy — The hypothesis of the study is that induction immunochemotherapy, followed by surgery or chemoradiation and consolidation Durvalumab immunotherapy, can significantly improve event-free survival in patients with resectable or borderline resectable NSCLC at stage IIIA/B compared to existing treatment methods.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Disease stage
Required: Stage IIIA, IIIB (IASLC/UICC 8)
Excluded: Stage N3 TUMORS (IASLC/UICC 8)
Selected patients with NSCLC stage IIIA/B: IIIA: one or more lymph node levels involved at EBUS/mediastinoscopy T1/T2 N2. IIIB: one or more lymph node levels involved at EBUS/mediastinoscopy T3/T4 N2.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: mediastinal irradiation
Prior treatments including prior mediastinal irradiation
Cannot have received: anti-PD-1 therapy
Exception: Permitted if no permanent discontinuation for toxicity, all AEs resolved to baseline, no ≥ Grade 3 immune-related AE or immune-related neurologic/ocular AE of any grade, no additional immunosuppression other than corticosteroids, no recurrence of AE if re-challenged, not currently requiring >10 mg prednisone or equivalent per day. Endocrine AE ≤ Grade 2 allowed if stably maintained and asymptomatic.
Patients who have received prior anti-PD-1, anti-PD-L1, or anti-CTLA-4
Cannot have received: anti-PD-L1 therapy
Exception: Permitted if no permanent discontinuation for toxicity, all AEs resolved to baseline, no ≥ Grade 3 immune-related AE or immune-related neurologic/ocular AE of any grade, no additional immunosuppression other than corticosteroids, no recurrence of AE if re-challenged, not currently requiring >10 mg prednisone or equivalent per day. Endocrine AE ≤ Grade 2 allowed if stably maintained and asymptomatic.
Patients who have received prior anti-PD-1, anti-PD-L1, or anti-CTLA-4
Cannot have received: anti-CTLA-4 therapy
Exception: Permitted if no permanent discontinuation for toxicity, all AEs resolved to baseline, no ≥ Grade 3 immune-related AE or immune-related neurologic/ocular AE of any grade, no additional immunosuppression other than corticosteroids, no recurrence of AE if re-challenged, not currently requiring >10 mg prednisone or equivalent per day. Endocrine AE ≤ Grade 2 allowed if stably maintained and asymptomatic.
Patients who have received prior anti-PD-1, anti-PD-L1, or anti-CTLA-4
Lab requirements
Blood counts
Hemoglobin ≥ 9.0 g/dL; ANC ≥ 1.5 × 10^9/L; Platelet count ≥ 100 × 10^9/L
Kidney function
Measured or calculated creatinine clearance ≥ 60 mL/min
Liver function
Serum bilirubin ≤ 1.5 × institutional ULN (except Gilbert's syndrome); ALT/AST ≤ 2.5 × institutional ULN
Cardiac function
Stable cardiac function (no MI within 6 months, no heart failure NYHA III-IV)
Adequate normal organ and bone marrow function as defined below: Hemoglobin ≥ 9.0 g/dL. ANC ≥ 1.5 × 10^9/L. Platelet count ≥ 100 × 10^9/L. Serum bilirubin ≤ 1.5 × institutional ULN. ALT/AST ≤ 2.5 × institutional ULN. Creatinine clearance ≥ 60 mL/min. Stable cardiac function (no MI within 6 months, no heart failure NYHA III-IV).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify